Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 867

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 867
---
 |     |       |      — |     |             |                            — |     |                |      9 |   |     |       |      9 |   |
| Total operating expenses        |     | $           |                        5,387 |     | $              | 8,145 |     | $     | 13,532 |     | $           |                        9,023 |     | $              | 12,142 |   |     | $     | 21,165 |   |

F-129

KINETA, INC.

Notes to Consolidated Financial Statements

Entity-Wide Disclosures

In addition to the segment information, the Company provides entity-wide disclosures about its products and services, geographic areas, and major customers.
The Company did not generate revenue for the year ended December 31, 2024 and generated license and collaboration revenue from one customer located in the United States for the year ended December 31, 2023.

The Company currently operates only in the United States and there were no long-lived assets outside of the United States as of December 31, 2024 and
2023.

16. Subsequent Events

The Company evaluated
subsequent events through the date these consolidated financial statements were issued to determine if they must be reported. The management of the Company determined there were no reportable subsequent events other than as described below.

Clinical Trial Funding Agreement

Subsequent to
December 31, 2024, pursuant to the Clinical Trial Funding Agreement, the Company received cash of $552,000 from TuHURA to reimburse the Company for clinical trial expenses related to KVA12123 and received cash of $250,000 as a loan.

Pacira Asset Sale

On January 8, 2025, Kineta’
subsidiary, KCP, entered into an exclusivity agreement (“KCP506 Exclusivity Agreement”) with Pacira Pharmaceuticals, Inc. (“Pacira”). Pursuant to the KCP506 Exclusivity Agreement, the Company received cash of $50,000 as an
exclusivity payment from Pacira in January 2025.

On February 4, 2025, KCP entered into an Asset Purchase Agreement (the “Pacira APA”) with
Pacira. Under the terms of the Pacira APA, Pacira will acquire certain assets from Kineta related to the development of KCP-506. The assets being acquired include intellectual property rights, assumed
contracts, permits, inventory